After a 27-month rollercoaster ride, can we expect a return to normal?
Battered biotech is reviving after booming and busting in spectacular fashion. M&A is heating up as pharma companies face up to their patent cliff. And drug sales growth forecasts continue skyward.
Big pharma had a smoother ride– not just relative to biotech, but as a defensive stalwart amid huge macro-economic pressures. Then of course there’s the unpredictability of China and a hard-to-read FDA to consider.
The Evaluate Pharma World Preview 2022 explores the future of the pharma and biotech landscape, based on Evaluate consensus forecasts out to 2028.
Download Now
Share
Related Blogs
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the ...
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...
